SG Americas Securities LLC Acquires 16,982 Shares of TG Therapeutics, Inc. $TGTX

SG Americas Securities LLC lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 27.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,357 shares of the biopharmaceutical company’s stock after purchasing an additional 16,982 shares during the quarter. SG Americas Securities LLC’s holdings in TG Therapeutics were worth $2,336,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Signature Wealth Management Partners LLC increased its stake in TG Therapeutics by 3.7% during the 3rd quarter. Signature Wealth Management Partners LLC now owns 11,180 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 400 shares in the last quarter. Amalgamated Bank lifted its stake in TG Therapeutics by 1.1% in the third quarter. Amalgamated Bank now owns 39,248 shares of the biopharmaceutical company’s stock valued at $1,418,000 after buying an additional 424 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of TG Therapeutics by 1.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company’s stock valued at $1,135,000 after buying an additional 441 shares during the period. Smartleaf Asset Management LLC increased its position in shares of TG Therapeutics by 21.0% during the third quarter. Smartleaf Asset Management LLC now owns 2,693 shares of the biopharmaceutical company’s stock worth $99,000 after acquiring an additional 467 shares in the last quarter. Finally, Bessemer Group Inc. raised its holdings in shares of TG Therapeutics by 117.1% during the third quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 486 shares during the period. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $33.53 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.29 and a current ratio of 4.10. The company has a 50-day simple moving average of $29.95 and a 200 day simple moving average of $31.52. TG Therapeutics, Inc. has a 52 week low of $25.28 and a 52 week high of $46.48. The company has a market capitalization of $5.35 billion, a price-to-earnings ratio of 12.10 and a beta of 1.76.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The company had revenue of $192.57 million during the quarter, compared to the consensus estimate of $192.15 million. During the same quarter in the previous year, the business posted $0.15 EPS. The firm’s revenue for the quarter was up 78.0% on a year-over-year basis. On average, sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 29th. JPMorgan Chase & Co. cut their price target on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a report on Monday, February 2nd. The Goldman Sachs Group increased their price objective on TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a report on Thursday, January 15th. Wall Street Zen lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a research note on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $50.00.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.